Aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Aspartate aminotransferase (AST, SGOT) =< 2.5 x ULNXx_NEWLINE_xXWithin 14 days of registration: Aspartate aminotransferase (AST) =< 2.5 x upper limits of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3.0 X ULN, within 14 days of registrationXx_NEWLINE_xXAspartate aminotransferase (AST) ? 2.5 × ULN without liver metastases; must be ? 5 × ULN with liver metastasesXx_NEWLINE_xXObtained =< 21 days prior to registration: Aspartate aminotransferase (AST) < 2.5 X ULN, with normal bilirubin; NOTE: Concomitant elevations in bilirubin and AST above 1.5 x ULN (upper limit of normal) is not permittedXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN obtained within 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) < 5 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST [SGOT]) ?2.5 × the ULN;Xx_NEWLINE_xXAspartate aminotransferase (AST) (SGOT) less than or equal to 3 x UNLXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma - then =< 5 x ULN obtained =< 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) =< 5 x normalXx_NEWLINE_xXObtained within 14 days prior to C1D1: Aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXObtained =< 21 days prior to registration: aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULNXx_NEWLINE_xXObtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 5 x ULNXx_NEWLINE_xXaspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastasesXx_NEWLINE_xXObtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x institutional ULNXx_NEWLINE_xXOBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Aspartate aminotransferase (AST) =< 2 x ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 X ULNXx_NEWLINE_xXINCLUSION - TREATMENT: Aspartate aminotransferase (AST) ? 5xXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if judged by the investigator to be related to liver metastasesXx_NEWLINE_xXWithin 14 days of the first dose of study drug: Aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 × ULN obtained within 14 days prior to initiating study treatment.Xx_NEWLINE_xXAspartate aminotransferase (AST) level =< 2.5 × ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) < 3 x ULN unless due to the underlying leukemia approved by the PIXx_NEWLINE_xXAspartate aminotransferase (AST) ? 3.0 x ULN (unless considered due to leukemic organ involvement)Xx_NEWLINE_xXAspartate aminotransferase (AST) greater than 2.0 times the ULN in the absence of known hepatic metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) > 45 U/LXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) level =< 2.5 x ULNXx_NEWLINE_xXObtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXWithin 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) unless demonstrated lymphoma involvement of the liver, performed within 14 days prior to day 1 of protocol therapyXx_NEWLINE_xXSerum aspartate aminotransferase (AST) ?3 × ULN (Grade ?1).Xx_NEWLINE_xXAspartate aminotransferase (AST) < 3 x ULN unless considered due to leukemic involvementXx_NEWLINE_xXAspartate aminotransferase (AST) ? 1.5 x ULNXx_NEWLINE_xXaspartate aminotransferase (AST) <= 3.0 x ULN*Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN (obtained within three days prior to study treatment)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN.Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN within 14 days of study registration.Xx_NEWLINE_xXAspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with documented metastatic disease to the liver).Xx_NEWLINE_xXAspartate aminotransferase (AST) within 2.5 x ULN unless there are liver metastases in which case, AST within 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN.Xx_NEWLINE_xXWithin 14 days prior to cycle 1 day 1 of treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN (5.0 x ULN if liver involvement)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) within 2.5 x ULN unless there are liver metastases in which case, AST within 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 2.5 x ULN obtained =< 7 days prior to registrationXx_NEWLINE_xXObtained within 14 days of randomization: Aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXDetermined within 3 weeks of treatment initiation: Aspartate aminotransferase (AST) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastasesXx_NEWLINE_xXaspartate aminotransferase (AST) ? 3.0 × ULN*Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN prior to biopsyXx_NEWLINE_xXAspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver metastases should have AST =< 5 x ULNXx_NEWLINE_xXCELL PROCUREMENT: Aspartate aminotransferase (AST) =< 3.0 x ULN, obtained within 72 hrs prior to procurementXx_NEWLINE_xXLYMPHODEPLETION: Aspartate aminotransferase (AST) =< 3.0 x ULN, obtained within 72 hrs prior to procurementXx_NEWLINE_xXWithin 14 days prior to planned start of treatment: Aspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) and AST <3x institutional ULN within 7 days prior to starting the study drug.Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x ULN for the laboratoryXx_NEWLINE_xXAspartate aminotransferase (AST) < 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2 x ULN for the laboratoryXx_NEWLINE_xXAspartate transaminase (aspartate aminotransferase [AST]) > 3.0 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).Xx_NEWLINE_xXPRIOR TO CELL PROCUREMENT: Aspartate aminotransferase (AST) ? 3 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the AST may be =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase =< 2.5 x institutional ULN obtained within 14 days of first treatmentXx_NEWLINE_xXAlanine aminotransferase and/or aspartate transaminase =< 3.0 x ULN or =< 5.0 x ULN if deemed to be elevated due to leukemiaXx_NEWLINE_xXAspartate aminotransferase =< 3 x ULNXx_NEWLINE_xXWithin 3 months of registration: Aspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN; =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 times the ULNXx_NEWLINE_xXWithin 14 days prior to study entry: Aspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 5.0 x normal institutional limits within 14 days of study entryXx_NEWLINE_xXAny serum aspartate aminotransferase (AST) is allowed but serum AST =< 34 IU/L is strongly encouragedXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN for the laboratoryXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3.5 x ULNXx_NEWLINE_xXAT THE TIME OF INFUSION: Aspartate aminotransferase (AST) ? 5 x normalXx_NEWLINE_xXTREATMENT: Aspartate aminotransferase (AST) < 5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN (must be within 7 days of MLA)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x ULN, obtained =< 14 days prior to registrationXx_NEWLINE_xXWithin 2 weeks of enrollment: Aspartate aminotransferase (AST) =< 3 x normal rangeXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 121 IU/LXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) > 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 3 times the ULNXx_NEWLINE_xXAspartate aminotransferase level (<=) 2.5* ULN, andXx_NEWLINE_xXAspartate aminotransferase (AST) within the reference range during screening evaluationXx_NEWLINE_xXAspartate aminotransferase (AST) > 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULNXx_NEWLINE_xXAspartate transaminase (AST) ? 2.5 x ULNXx_NEWLINE_xXTo be performed within 14 days prior to day 1 of protocol therapy: aspartate aminotransferase (AST) =< 3 x ULN\r\n* If hepatic involvement by lymphoma: AST =< 5 x ULNXx_NEWLINE_xXFor high risk and very high risk CLL-IPI (Arms A and B) only; obtained ? 30 days prior to randomization: Aspartate aminotransferase (aspartate transaminase [AST]) ? 3 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)Xx_NEWLINE_xXWithin 14 days prior to day 1 of protocol therapy unless otherwise stated: Aspartate aminotransferase (AST) =< 2 x ULNXx_NEWLINE_xXAt cycle 1 day 1 pre-dosing: Aspartate aminotransferase (AST) >= 2.5 x the ULNXx_NEWLINE_xXTo be performed within 28 days prior to day 1 of protocol therapy: Aspartate aminotransferase (AST) =< 2.5 x ULN if no liver metastases or =< 5 x ULN if liver metastasesXx_NEWLINE_xXAspartate aminotransferase (aspartate transaminase [AST]) =< 2.5 x ULN, obtained =< 7 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN for the laboratoryXx_NEWLINE_xXObtained within 30 days prior to registration: Aspartate aminotransferase (AST) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2 x ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 3 x ULN (obtained =< 14 days prior to registration)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN for the laboratoryXx_NEWLINE_xXAspartate aminotransferase (AST) < 2.5 x ULN of the institutional normal reference rangeXx_NEWLINE_xXAspartate aminotransferase (AST) must be =< 1.5 x ULN for the labXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasisXx_NEWLINE_xXAspartate transaminase (AST) < 2.5 times the ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis), obtained =< 21 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma – then =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) ? 2.0 X ULN,Xx_NEWLINE_xXAspartate transaminase (AST) at least 2.5 ULNXx_NEWLINE_xXAspartate aminotransferase (AST) ? 2 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULN within 14 days prior to study registrationXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) without, and =< 5 x ULN with hepatic metastasisXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase less than or equal to 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 5 x ULNXx_NEWLINE_xXWithin 72 h of initiating study treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for liver metastases (mets)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 3 times ULN for age obtained =< 7 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 X ULNXx_NEWLINE_xXand aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastasesXx_NEWLINE_xXObtained =< 21 days prior to registration: Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) ? 1.5 x ULN unless there is hepatic involvement, then 3 x ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 3 x ULNXx_NEWLINE_xXWithin 30 days prior to initiation of protocol treatment: Aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are presentXx_NEWLINE_xXAspartate aminotransferase (AST) =< 5 x institutional upper limits of normal (ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x the ULN for age (in the absence of hepatic involvement of tumor)Xx_NEWLINE_xXAspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastasesXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x normal limitsXx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registrationXx_NEWLINE_xXAspartate aminotransferase > 100 IU/LXx_NEWLINE_xXAspartate aminotransferase (AST) ?3 × ULNXx_NEWLINE_xXAspartate aminotransferase ?3 × ULN for the reference lab (?5 × ULN for subjects with known hepatic metastases)Xx_NEWLINE_xXSerum aspartate transaminase (AST) >2.5x ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 3 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN); if liver metastases are present, =< 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) <2.5 x UNLXx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 X ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x the ULN (in the absence of hepatic involvement of tumor)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 times ULNXx_NEWLINE_xXAspartate transaminase (AST) =< 5 x ULNXx_NEWLINE_xXAlanine aminotransferase and/or aspartate transaminase < 3.0 x ULN (or < 5.0 x ULN if deemed to be elevated due to leukemia)Xx_NEWLINE_xXAspartate aminotransferase (AST) =< 3 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 5.0 x ULNXx_NEWLINE_xXAspartate aminotransferases (AST) =< 3 times ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2 x institutional ULNXx_NEWLINE_xXAspartate aminotransferase level (AST) =< 3 x ULN, within 30 days prior to enrollmentXx_NEWLINE_xXAspartate aminotransferase (AST) =< 5 x normalXx_NEWLINE_xXObtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (subjects with documented liver metastases should have AST =< 5 x ULN)Xx_NEWLINE_xXAspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present, then < 5 × ULNXx_NEWLINE_xXAspartate aminotransferase (AST) < 5 X institutional ULNXx_NEWLINE_xXAspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for subjects with liver metastases, obtained within 14 days prior to C11-AMT PET scanXx_NEWLINE_xXAspartate aminotransferase (AST) =< 1.5 x ULNXx_NEWLINE_xXAspartate aminotransferase (AST) > 3 x ULNXx_NEWLINE_xXAspartate aminotransferase =< 45 IU/dLXx_NEWLINE_xXCohort 2 (mild): Bilirubin > 1-1.5 × upper limit of the normal range (ULN) or aspartate aminotransferase (AST) > ULN, but bilirubin ? ULNXx_NEWLINE_xX